Health technology assessment in T?rkiye: Current status and perspectives on future implementation

被引:2
|
作者
Atikeler, E. Kagan [1 ]
Fasseeh, Ahmad Nader [2 ,3 ]
Mantel-Teeuwisse, Aukje K. [1 ]
Caliskan, Zafer [4 ]
Oner, Z. Guelsen [5 ]
Kizilay, Harun [6 ]
Kalo, Zoltan [7 ,8 ]
Goettsch, Wim [1 ,9 ]
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[2] Eotvos Lorand Univ, Fac Social Sci, Doctoral Sch Sociol, Budapest, Hungary
[3] Syreon Middle East, Cairo, Egypt
[4] Hacettepe Univ, Dept Econ, Ankara, Turkiye
[5] Social Secur Inst, Ankara, Turkiye
[6] Selcuk Univ, Hlth Sci Inst, Dept Pharmacol & Toxicol, Konya, Turkiye
[7] Semmelweis Univ, Ctr Hlth Technol Assessment, Budapest, Hungary
[8] Syreon Res Inst, Budapest, Hungary
[9] Natl Hlth Care Inst, Diemen, Netherlands
关键词
Turkish healthcare decision-making; Health technology assessment (HTA); HTA implementation; Economic evaluation; Evidence-based health policy; T?rkiye(Turkey); HTA;
D O I
10.1016/j.hlpt.2022.100701
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: : Turkiye's health care system reforms have led not only to increased access to health care but also to rising pharmaceutical expenditures. Therefore, health technology assessment (HTA) has become an important tool for evaluating priorities in reimbursement and budget allocation. Our study aimed to describe the current HTA environment in Turkiye and explore long-term perspectives from a broad spectrum of Turkish stakeholders on the development of HTA in the next ten years.Methods: : In 2019, we used a convenience sampling method to conduct an online survey with stakeholders from different areas in the health system. Additional face-to-face discussions were conducted to clarify answers when needed. We assessed the current evaluation process for pharmaceuticals and examined the need for HTA in Turkiye. Online survey data were extracted into Microsoft Excel for analysis. Quantitative data were summarised descriptively.Results: : A total of 27 Turkish stakeholders completed the survey; 21 were employed in the public sector, and 6, in the private sector. The majority of participants (18/27) suggested introducing HTA for all new health tech-nologies considered for public reimbursement and instituting an additional review process for currently reim-bursed technologies. Most respondents (25/27) agreed that a threshold for cost-effectiveness should be applied in the next ten years.Conclusion: : The stakeholders concurred that Turkiye must implement an HTA process soon. However, further discussion and interaction between stakeholders are essential to ensure a broad commitment to the imple-mentation of a structured HTA process in Turkiye.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Retapamulin: Current Status and Future Perspectives
    Goudarzi, Mehdi
    Khoshbayan, Amin
    Taheri, Fateme
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2021, 16 (04):
  • [42] Pharmacogenomics: current status and future perspectives
    Pirmohamed, Munir
    NATURE REVIEWS GENETICS, 2023, 24 (06) : 350 - 362
  • [43] Immunotherapy: Current Status and Future Perspectives
    Charalampos S. Floudas
    Gagandeep Brar
    Tim F. Greten
    Digestive Diseases and Sciences, 2019, 64 : 1030 - 1040
  • [44] Pharmacogenetics: Current Status and Future Perspectives
    Guchelaar, Henk-Jan
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (02) : 135 - 135
  • [45] Pharmacogenomics: current status and future perspectives
    Munir Pirmohamed
    Nature Reviews Genetics, 2023, 24 : 350 - 362
  • [46] Immunotherapy: Current Status and Future Perspectives
    Floudas, Charalampos S.
    Brar, Gagandeep
    Greten, Tim F.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (04) : 1030 - 1040
  • [47] UMIN - Current Status and Future Perspectives
    UMIN Center, The University of Tokyo Hospital, Tokyo, Japan
    不详
    International Medical Informatics Association (IMIA), 1879, 1068-1072 (2004):
  • [48] UMIN - Current status and future perspectives
    Kiuchi, T
    Igarashi, T
    MEDINFO 2004: PROCEEDINGS OF THE 11TH WORLD CONGRESS ON MEDICAL INFORMATICS, PT 1 AND 2, 2004, 107 : 1068 - 1072
  • [49] THE ONCOGENES - CURRENT STATUS AND FUTURE PERSPECTIVES
    KOUYOUMDJIAN, JC
    FEUILHADE, F
    RYMER, JC
    RODRIGUES, LEA
    REVISTA BRASILEIRA DE MEDICINA, 1988, 45 (05) : 143 - 149
  • [50] Bedaquiline: Current status and future perspectives
    Khoshnood, Saeed
    Goudarzi, Mehdi
    Taki, Elahe
    Darbandi, Atieh
    Kouhsari, Ebrahim
    Heidary, Mohsen
    Motahar, Moloudsadat
    Moradi, Melika
    Bazyar, Hadi
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 48 - 59